EZH2 and breast carcinoma: MiR-200c and miR-214 were previously reported to target BMI1 and EZH2, respectively, in studies that showed that miR-214 targets Ezh2 in skeletal muscle and embryonic stem cells and that miR-200c targets BMI1 in breast cancer stem cells [33], [46].